Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial"

Jan Westerink; Frank Visseren

doi:10.1161/ATVBAHA.117.309295

Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial"

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Article number	e53
Journal	Arteriosclerosis, Thrombosis and Vascular Biology
Volume	37
Issue number	5
DOIs	https://doi.org/10.1161/ATVBAHA.117.309295
Publication status	Published - 2017

Keywords

Letter

Access to Document

10.1161/ATVBAHA.117.309295

Cite this

Westerink, J., & Visseren, F. (2017). Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial". Arteriosclerosis, Thrombosis and Vascular Biology, 37(5), Article e53. https://doi.org/10.1161/ATVBAHA.117.309295

Westerink, Jan ; Visseren, Frank. / Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting : The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial". In: Arteriosclerosis, Thrombosis and Vascular Biology. 2017 ; Vol. 37, No. 5.

@article{644b1566c8a04c3990149651d54a3594,

title = "Letter by Westerink and Visseren Regarding Article, {"}Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial{"}",

keywords = "Letter",

author = "Jan Westerink and Frank Visseren",

year = "2017",

doi = "10.1161/ATVBAHA.117.309295",

language = "English",

volume = "37",

journal = "Arteriosclerosis, Thrombosis and Vascular Biology",

issn = "1079-5642",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

Westerink, J & Visseren, F 2017, 'Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial"', Arteriosclerosis, Thrombosis and Vascular Biology, vol. 37, no. 5, e53. https://doi.org/10.1161/ATVBAHA.117.309295

Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial". / Westerink, Jan ; Visseren, Frank.
In: Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 37, No. 5, e53, 2017.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting

T2 - The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial"

AU - Westerink, Jan

AU - Visseren, Frank

PY - 2017

Y1 - 2017

KW - Letter

UR - http://www.scopus.com/inward/record.url?scp=85020273577&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.117.309295

DO - 10.1161/ATVBAHA.117.309295

M3 - Comment/Letter to the editor

C2 - 28446474

SN - 1079-5642

VL - 37

JO - Arteriosclerosis, Thrombosis and Vascular Biology

JF - Arteriosclerosis, Thrombosis and Vascular Biology

IS - 5

M1 - e53

ER -

Westerink J , Visseren F. Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial". Arteriosclerosis, Thrombosis and Vascular Biology. 2017;37(5):e53. doi: 10.1161/ATVBAHA.117.309295

Keywords

Access to Document

Other files and links

Cite this